Role of pharmacogenomics in the treatment of tuberculosis: a review

References

• World Health OrganisationGlobal TB report2010
   Google Scholar
• CroftonJGlobal challenge of TBLancet199434489226097914971
   PubMed Web of Science ®Google Scholar
• MenziesDBenedettiAPayderAEffect of duration and intermittency of rifampin on TB treatment outcomes: a systematic review and meta-analysisPLoS Med200969e100014619753109
   PubMed Web of Science ®Google Scholar
• VesellESPharmacokinetic perspectives gained from twin and family studiesPharmacol Ther19894135355522654965
   PubMed Web of Science ®Google Scholar
• KalowWThangBKEndreyiLHypothesis: comparisons of inter and intra-individual variations can substitute for twin studies in drug researchPharmacokinetics199884283289
   Google Scholar
• EvansWERellingMVPharmacogenomics: translating functional genomics into rational therapeuticsScience1999286543948749110521338
   PubMed Web of Science ®Google Scholar
• EvansWEJohnsonJAPharmacogenomics: the inherited basis for inter individual differences in drug responseAnnu Rev Genomics Hum Genet2001293911701642
   PubMed Web of Science ®Google Scholar
• McLeodHLEvansWEPharmacogenomics: unlocking the human genome for better drug therapyAnnu Rev Pharmacol Toxicol20014110112111264452
   PubMed Web of Science ®Google Scholar
• LehmannHRyanEFamilial incidence of low pseudo cholinesterase levelLancet1956271693412413347100
   PubMed Web of Science ®Google Scholar
• AlvingASCarsonPEFlanaganCLEnzymatic deficiency in primaquine-sensitive erythrocytesScience1956124322048448513360274
   PubMed Web of Science ®Google Scholar
• HughesHBBiehlJPJonesAPSchmidtLHMetabolism of isoniazid in man as related to the occurrence of peripheral neuritisAm Rev Tuberc195470226627313180863
   PubMedGoogle Scholar
• EvansDAManleyKAMcKusickVAGenetic control of isoniazid metabolism in manBr Med J19602519748549113820968
   PubMed Web of Science ®Google Scholar
• SachidanandamRWeissmanDSchmidtSCA map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature2001409682292893311237013
   PubMed Web of Science ®Google Scholar
• EvansWERellingMVMoving towards individualized medicine with pharmacogenomicsNature2004429699046446815164072
   PubMed Web of Science ®Google Scholar
• EvansWEPharmacogenomics: marshalling the human genome to individualise drug therapyGut200352Suppl IIii10ii1812651877
   PubMed Web of Science ®Google Scholar
• [No authors listed]Pharmacogenomics Available at: http://en.wikipedia.org/wiki/pharmacogenomics. Accessed August 7, 2012
   Google Scholar
• EllardGAGammonPTPharmacokinetics of isoniazid metabolism in manJ Pharmacokinet Biopharm19764283113950592
   PubMedGoogle Scholar
• Raghupati SarmaGIsoniazid metabolism in man and its therapeutic implicationsProceedings of the Symposium on Clinical Pharmacokinetics1978
   Google Scholar
• RoyPDMajumderMRoyBPharmacogenomics of anti-TB drug-related hepatotoxicityPharmacogenomics20089331132118303967
   PubMed Web of Science ®Google Scholar
• WeinerMPeloquinCABurmanWEffects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrationsAntimicrob Agents Chemother201054104192420020660695
   PubMed Web of Science ®Google Scholar
• ChigutsaEVisserMESwartECThe SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implicationsAntimicrob Agents Chemother20115594122412721709081
   PubMed Web of Science ®Google Scholar
• TostmannABoereeMJAarnoutseAntituberculosis drug-induced hepatotoxicity: concise up-to-date reviewJ Gasteroenterol Hepatol2008232192202
   PubMed Web of Science ®Google Scholar
• Biomedical Research and Training InstitutePharmacogenetics and drug-drug interactions in the treatment of tuberculosis – potential clinical implications in Zimbabwe102011 Available from: http://www.brti.co.zw
   Google Scholar
• CascorbiLRootsIPitfalls in N-acetyl transferase 2 genotypingPharmacogenetics19999112312710208651
   PubMedGoogle Scholar
• Kinzig-SchippersMTomalik-ScharteDJetterAShould we use N-acetyl transferase type 2 genotyping to personalize isoniazid doses?Antimicrob Agents Chemother20054951733173815855489
   PubMed Web of Science ®Google Scholar
• ParkinDPVandenplasSBothaFJTrimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosisAm J Respir Crit Care Med19971555171717229154882
   PubMed Web of Science ®Google Scholar
• KitaTTanigawaraYChikazawaSN-acetyl transferase-2 genotype correlated with isoniazid acetylation in Japanese tuberculous patientsBiol Pharm Bull200124554454911379777
   PubMed Web of Science ®Google Scholar
• MitchisonDADrug resistance in mycobacteriaBr Med Bull198440184906442876
   PubMed Web of Science ®Google Scholar
• DonaldPRSirgelFABothaFJThe influence of human N-acetyl transferase genotype on the early bactericidal activity of isoniazidClin Infect Dis200439101425143015546075
   PubMed Web of Science ®Google Scholar
• WeinerMBurmanWVernonALow isoniazid concentrations and outcome of tuberculosis treatment with once weekly isoniazid and rifapentineAm J Respir Crit Care Med2003167101341134712531776
   PubMed Web of Science ®Google Scholar
• SelkonJBFoxWGangadharamPRJRate of inactivation of isoniazid in south Indian patients with pulmonary tuberculosis-2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PASBull World Health Organ19612577979213910443
   PubMed Web of Science ®Google Scholar
• [No authors listed]Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosisBr Med J1973258577114633061
   PubMed Web of Science ®Google Scholar
• [No authors listed]Controlled comparison of oral twice-weekly and three once weekly regimens in the initial treatment of pulmonary tuberculosisBull World Health Organ19704311432065312317
   PubMed Web of Science ®Google Scholar
• [No authors listed]Controlled comparison of two fully supervised once weekly regimens in the treatment of newly diagnosed pulmonary tuberculosisTubercle197354123454204397
   PubMedGoogle Scholar
• SarmaGRKailasamSMitchisonDAStudies of serial plasma isoniazid concentrations with different doses of a slow release preparation of isoniazidTubercle1975564314323779186
   PubMedGoogle Scholar
• GurumurthyPRamachandranGHemanth KumarAKDecreased bio-availability of rifampin and other anti-TB drugs in patients with advanced HIV diseaseAntimicrob Agents Chemother200448114473447515504887
   PubMed Web of Science ®Google Scholar
• RamachandranGHemanth KumarAKRajasekaranSAcetylator status influences bioavailability of isoniazid in patients with advanced HIV diseaseSAARC J Tuberc Lung Dis HIV/AIDS2005II2912
   Google Scholar
• GurumurthyPRaghupati SarmaGJayasankarKSingle-dose pharmacokinetics of isoniazid and rifampicin in patients with chronic renal failureInd J Tub199239221228
   Google Scholar
• DonaldPRParkinDPSeifartHIThe influence of dose and N-acetyl transferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazidPharmacokinet Dispos2007637633639
   Google Scholar
• WilkinsJJLangdonGMcIlleronHVariability in the population pharmacokinetics of isoniazid in South African tuberculosis patientsBr J Clin Pharmacol2011721516221320152
   PubMed Web of Science ®Google Scholar
• JeenaPMBishaiWRPasipanodyaJGGumboTIn silico children and the glass mouse model; clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosisAntimicrob Agents Chemother201155253954521098246
   PubMed Web of Science ®Google Scholar
• McIlleronHWillemseMWerelyCJIsoniazid plasma concentrations in a cohort of south African children with tuberculosis: implications for international pediatrics dosing guidelinesClin Infect Dis200948111547155319392636
   PubMed Web of Science ®Google Scholar
• CranswickNMulhollandKIsoniazid treatment of children: can genetics help guide treatment?Arch Dis Child200590655155315908610
   PubMed Web of Science ®Google Scholar
• SchaafHSParkinDPSeifartHIIsoniazid pharmacokinetics in children treated for respiratory tuberculosisArch Dis Child200590661461815908628
   PubMed Web of Science ®Google Scholar
• DevadattaSGangadharamPRJAndrewsRHPeripheral neuritis due to isoniazidBull World Health Organ19602358759813722334
   PubMedGoogle Scholar
• No authors listedThe prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 2. An assessment of the prophylactic effect of pyridoxine in low dosageBull World Health Organ19632945748114099673
   PubMed Web of Science ®Google Scholar
• MitchellJRZimmermanHJIshakKGIsoniazid liver injury: clinical spectrum, pathology and probable pathogenesisAnn Intern Med1976842181192766682
   PubMed Web of Science ®Google Scholar
• EllardGASlow release preparation of isoniazid: pharmacological aspectsBull Int Union Tuberc1976511143154
   Google Scholar
• SarmaGRImmanuelCKailasamSRifampin induced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampinAm Rev Respir Dis19861336107210753717759
   PubMed Web of Science ®Google Scholar
• OhnoMYamaguchiIYamamotoISlow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin induced hepatotoxicityInt J Tuberc Lung Dis20004325626110751073
   PubMed Web of Science ®Google Scholar
• HuangYSChernHDSuWJPolymorphisms of N-acetyl transferase 2 gene as susceptibility risk factors for anti-tuberculosis drug induced hepatitisHepatology200235488388911915035
   PubMed Web of Science ®Google Scholar
• ChoHJKohWJRyuYJGenetic polymorphisms of NAT2 and CYP2E1 associated with anti tuberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosisTuberculosis (Edinb)200787655155617950035
   PubMed Web of Science ®Google Scholar
• MahmoudBLGhozziHKamounAPolymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosisPathol Biol (Paris)82011 [Epub ahead of print.]
   Google Scholar
• HiratsukaMYKushikawaYTakekumaMGenotyping of the N-acetyltransferase polymorphism in the prediction of adverse reactions to isoniazid in Japanese patientsDrug Metab Pharmacokinet200217435736215618686
   PubMedGoogle Scholar
• WangPYXieSYHaoQXiangBFNAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: meta-analysisInt J Tuberc Lung Dis201216558959522409928
   PubMed Web of Science ®Google Scholar
• Leiro-FernandezVValverdeDVazques-GallardoRN-acetyl transferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in CaucasiansInt J Tuberc Lung Dis201115101403140822283902
   PubMed Web of Science ®Google Scholar
• RoyBChowdhuryAKunduSIncreased risk of anti-tuberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 null mutationJ Gastroenterol Hepatol20011691033103711595069
   PubMed Web of Science ®Google Scholar
• VuilleumierNRossierMFChiappeACYP2E1 genotype and isoniazid induced hepatotoxicity in patients treated for latent tuberculosisEur J Clin Pharmacol200662642342916770646
   PubMedGoogle Scholar
• NelsonSDMitchellJRTimbrellJASnodgrassWRCorcoranGB3rdIsoniazid and iproniazid: activation of metabolites to toxic intermediates in man and ratScience197619342569019037838
   PubMed Web of Science ®Google Scholar
• YueJPengRXYangJKongRLiuJCYP2E1 mediated isoniazid induced hepatotoxicity in ratsActa Pharmacol Sin200425569970415132840
   PubMed Web of Science ®Google Scholar
• HuangYSChernHDSuWJCytochrome P450 2 E1 genotype and the susceptibility to anti tuberculosis drug induced hepatitisHepatology200337492493012668988
   PubMed Web of Science ®Google Scholar
• LeeSWChungLSHuangHHNAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitisInt J Tuberc Lung Dis201014562262620392357
   PubMed Web of Science ®Google Scholar
• RoyBGhoshSKSutradharDPredisposition of anti-tuberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatrics patientsJ Gastroenterol Hepatol200621478178616677173
   PubMed Web of Science ®Google Scholar
• StrangeRCJonesPWFryerAAGlutathione S-transferase: genetics and role in toxicologyToxicol Lett2000112–113357363
   PubMed Web of Science ®Google Scholar
• SimonTBecquemontLMary-KrauseMCombined glutathione S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicityClin Pharmacol Ther200067443243710801254
   PubMed Web of Science ®Google Scholar
• HuangYSSuWJHuangYHGenetic polymorphisms of managanese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1 and the susceptibility to drug induced liver injuryJ Hepatol200747112813417400324
   PubMed Web of Science ®Google Scholar
• SharmaSKBalamuruganASahaPKEvaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuberculosis treatmentAm J Respir Crit Care Med2002166791691912359646
   PubMed Web of Science ®Google Scholar
• GrossetJHRosenthalIMZhangMDose ranging comparison of rifampin and rifapentine in combination with isoniazid and pyrazinamide in the mouse model of tuberculosisAbstract A-1825 presented at the 46th Annual Meeting of American Society for Microbiology and Infectious Diseases Society of AmericaOctober 25–28, 2008Washington DC
   Google Scholar
• JayaramRGaonkarSKaurPPharmacokinetics and pharmacodynamics of rifampin in an aerosol infection model of tuberculosisAntimicrob Agents Chemother20034772118212412821456
   PubMed Web of Science ®Google Scholar
• JiBTruffot PernotCLacroixCEffectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in miceAm Rev Respir Dis19931486 Pt 1154115468256897
   PubMed Web of Science ®Google Scholar
• ZhaoHLiRWangQMaternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese familyAm J Hum Genet200474113915214681830
   PubMed Web of Science ®Google Scholar
• YamadaSTangMRichardsonKGenetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse populationPharmacogenomics20091091433144519761367
   PubMed Web of Science ®Google Scholar